

OHE Annual Report to the Charity Commission 2022



Mireia Jofre-Bonet
Graham Cookson
George Bray
Claire Green

OCTOBER 2023

OHE Annual Report to the Charity Commission 2022

Mireia Jofre-Bonet

Office of Health Economics, London

Graham Cookson

Office of Health Economics, London

George Bray

Office of Health Economics, London

Claire Green

Office of Health Economics, London

Please cite this report as:

OHE, 2023. OHE Annual Report to the Charity Commission 2022, London: Office of Health Economics.

Corresponding Author:

Mireia Jofre-Bonet

mjofre-bonet@ohe.org

Table of Contents

OHE Annual Report to the Charity Commission 2022	i
Table of Contents	ii
About OHE	1
Our year in numbers	3
Key areas of impact.....	3
Administrative information	4
Introduction	5
Activities undertaken in fulfilment of charitable objects.....	6
Financial review	11
Structure, governance, and management in 2022	14
Epilogue	15
APPENDIX: 2022 Research Summary.....	16

About OHE

MISSION STATEMENT

Support better health care policies by providing insightful economic and statistical analyses of critical issues.

HOW WE ARE ORGANISED

The Office of Health Economics (OHE) is a charity with registered charity number 1170829. A senior management team manages OHE and our governance is the responsibility of the Board of Trustees.

The **Board of Trustees** has three sub-committees with advisory roles:

- **Research Committee:** Provides advice and guidance to OHE on its research programme
- **Policy Committee:** Advises OHE on engaging with policymaking and meeting its Charitable Objects
- **Management Committee:** Assists OHE with its operational and business planning.

The Office of Health Economics wholly owns OHE Consulting Limited, which carries out consulting work for third parties. Its profits fund our research and charity activities.

OHE is an **Independent Research Organisation (IRO)**. This status was awarded in 2020 by UK Research and Innovation (UKRI) which – through the seven Research Councils, Innovate UK and Research England – allocates more than £7 billion in research funding, primarily from the Science Budget of the Department for Business, Energy and Industrial Strategy (BEIS).

IRO status recognises the high quality of OHE's independent research, on par with the UK's higher education institutions, and makes us eligible to apply for UKRI funding on the same terms to better fulfil our charitable aims.






WHO WE ARE, HOW AND WHERE WE WORK






By the end of 2022, the OHE team comprised one Chief Executive Officer; one Deputy Chief Executive Officer, one Chief Research Officer & Head of Education; one Emeritus Director & Senior Research Fellow; four Directors; one Associate Director; four Senior Principal Economists; three Principal Economists; four Senior Economists; one Business Executive; nine Economists; one Head of Academy and three Administrative Support staff, and two MSc student fellows. Also, in 2022 OHE had nine Honorary Research Fellows.






We emphasise projects that tackle impactful policy and strategic issues with current and future significance. Our work involves stakeholders, clients, and external experts to obtain crucial new policy insights and identify strategies and optimal choices.

Although OHE is based in London, we undertake projects both in the UK and internationally. We work collaboratively with a wide network of academics and other partners worldwide.




Our year in numbers

		28 peer-reviewed external publications		7.1 impact factor for OHE research over five years
RESEARCH		37 blogs authored by OHE		11,200 publication downloads from OHE's website

		2500+ delegates reached through online and in-person events		4 profile-raising events including our Annual Lecture
EVENTS		11 webinars, masterclasses and seminars		73 presentations at external conferences

		87 countries reached through Educational content		5,572 Twitter and 7,653 LinkedIn followers
GLOBAL REACH		14 global applications for the inaugural Innovation Policy Prize		130,186 website users

Key areas of impact

	Antimicrobial Resistance (AMR)
	Digital health
	Precision oncology

Administrative information

Trustees and Directors

By the end of 2022

Anita Charlesworth	The Health Foundation Chair
Richard Torbett	(APBI) Trustee
Werner Brouwer	ESHPM (OHE) Trustee (appointed 31 st March 2022)
Patrick Holmes	Pfizer (ABPI) Trustee (appointed 31 st January 2022)
Margaret Kyle	Mines ParisTech (OHE) (appointed 14 th January 2022)
Susan Rienow	Pfizer (ABPI) (appointed 5 th October 2022)

Other:

Mr U Bose	(Boehringer Ingelheim) Trustee (resigned 31 st October 2022)
Prof B Jonsson	Trustee (resigned 14 th January 2022)
Prof M Drummond	Trustee (resigned 14 th January 2022)
Mr B S Sahota	Trustee (resigned 5 th October 2022)

Registered Office

2nd Floor Goldings House, Hay's Galleria, 2
Hay's Lane, London, SE1 2HB

Charity number: 1170829

Company number: 09848965

Auditor

BDO LLP

Statutory Auditor & Chartered Accountants
2 City Place
Beehive Ring Road
Gatwick
West Sussex RH6 0PA

Bankers

National Westminster Bank Plc

PO Box 113
Cavell House
2A Charing Cross Road
London

Senior Management

Chief Executive Officer

Prof Graham Cookson

Deputy Chief Executive Officer

Prof Lotte Steuten

Chief Research Officer and Head of Education

Prof Mireia Jofre-Bonet

Directors:

Charlotte Ashton

Martina Garau

Chris Skedgel

Tim Watson

Associate Directors:

Grace Hampson

Introduction

This is the sixth report to the Charity Commission for England and Wales since becoming a registered charity in December 2016.

This **Charity Report for 2022** includes the current document highlighting our work and the required financial information. The Appendix, **Research Summary of 2022 for the Charity Report**, based on the report submitted to the Research Committee in February of 2022, provides OHE's research activity for 2022 in detail.

The **Charity Report for 2022** shows yet again how OHE is committed to its charitable objects of advancing the education of the public in general/health care payers/policymakers on the subject of health economics and healthcare policy. Moreover, OHE uses health economics methods to produce evidence-based health policy and management, contributing to a more efficient and effective health care system.

Beyond OHE's charitable objects at OHE, we also support:

- The advancement of evidence-based health care policy by engaging in research on the economics of health, health care systems and the life sciences industry
- Research for the effective and efficient use of health care resources by advancing the use of economic approaches to support decision making; and
- Decision-making and awareness of health care policy issues by promoting debate and disseminating relevant health economics research.¹

¹ The term health economics shall mean the application of economic theory, models and empirical techniques to the analysis of decision making by people, health care providers and governments with respect to health and health care.

Activities undertaken in fulfilment of charitable objects

In this report aims we provide an account of OHE's performance in its **Charitable Purpose** and its **Impact** as defined below:

Charitable Purpose – Deliver on OHE Charitable Objects and maintain OHE social purpose, where the charitable objects are:

To advance the education of the public in general/healthcare payers/policymakers (particularly patients and healthcare professionals) about health economics and healthcare policy.

Activities in furtherance of this will include, but not exclusively:

- Promotion of evidence-based health care policy by carrying out research on the economics of health, health care systems and the life sciences industry,
- promotion of effective and efficient use of health care resources by advancing the use of economic approaches to support decision making; and
- facilitating decision-making and awareness of health care policy issues by encouraging debate and disseminating relevant health economics research.

Impact – Have a measurable impact on health care policy and decision-making.

As these two aims overlap, i.e., the impact is embedded in the Charitable Objects, we report our activity as follows:

1. **Research Activity** that promotes evidence-based healthcare policy and the effective and efficient use of healthcare resources
2. **Dissemination and Education Activities** that advance the education of the public/general health care payers/policymakers about health economics and healthcare policy
3. **Events** that encourage debate facilitate decision-making and increase awareness of health care policy issues

4. **Impact** summarised as a list indicative of the resonance of OHE's research or activities in decision-making in health care

The snapshot of activity and output above illustrates visually the breadth of OHE's research activity, events, dissemination, and education activities that encourage exchanging ideas and increasing awareness of health care policy issues, as of December 2022. Below is a summary of these activities before we go into more detail in the following sections.

	Promotion of evidence-based health care policy, by carrying out research on the economics of health, health care systems and the life sciences industry;	Facilitation of decision making and awareness of health care policy issues, by encouraging debate and dissemination of relevant health economics research.
Impact and Evidence	8 OHE publications (reports)	OHE Innovation Policy Prize
	29 Peer-reviewed journal publications and 1 book chapter	2 x Masterclasses • Severity in Value Assessment: From Principle to Practice • Multi-Indication Therapies
	40 Blog posts	
	75 Presentations at conferences	Lunchtime Seminar • The Value of a QALY Towards the End of Life and its Determinants: Experimental Evidence
		Annual Lecture • Universal Health Coverage: more than just old wine in a new bottle?
		4 x Webinars (non-sponsored) • Do We Need Animal Health Economics? • Can we "Netflix" the Broken Antibiotics Market? • Vaccines, Antivirals, Lockdowns & COVID-19: Learnings from the Pandemic • Insights from 2022 & Emerging Issues for 2023
		2x sponsored Webinars • Payment models • Health Technology Assessment for gene therapies

All OHE research aims to promote effective and efficient use of health care resources but more directly the research themes of VADM and POIHS.

To avoid duplication, in the following account of our objectives, we refer to the summary of research outputs and activities, which is an updated version of the one submitted to the Research Committee and the Board of Trustees in December 2022.

1. Research activity

As summarised in the research report attached, OHE's staff had published 29 external peer reviewed journal articles, 1 book chapter and 8 OHE reports (we do not include the 2021 Charity report although this is also available online), engaged in 75 presentations, and written 40 blogs up to the end of December 2022. OHE also published eight OHE consultancy reports, available online.

Many publications are in journals with a high reputation and/or high impact. Moreover, the number of downloads of the OHE's publications/reports was 12.6k by the end of December, showing a sound diffusion.

OHE's research activity not only includes publications but also research supported by our CORE grant. These CORE research-funded projects serve two purposes:

1. Fund the staff's own research in the form of pilots and studies that can lead to funded research.
2. Support the publication of reports and research in peer-reviewed journals in the absence of funding for this activity.

CORE-funded research showcases OHE's breadth and depth capabilities, attracting further funding (and consultancy work). As reported in the Research Summary in the Appendix, during 2022, there were 19 active CORE-funded research projects, including Economics of Innovation and Decision, Value and Affordability, the most active themes, with 6 and 7 projects, respectively.

Other research and dissemination outputs: In terms of outputs, OHE staff produced thirty-seven external publications (36 peer-reviewed), 5 brown bag and lunchtime seminars, 1 Annual Lecture, 6 Webinars 2 masterclasses and 75 external presentations, and 40 blogs. OHE celebrated its 60th Anniversary in 2022 and as such hosted two events to celebrate this milestone.

Research awards from prestigious funders and funded research projects: In 2022, OHE held £1.151m of live research grants of which 48% (£551,900) came from prestigious funders. Research projects are more likely to be multi-year engagements than consulting projects, and due to the phasing of these grants OHE has recognised (i.e., completed) £396k of research in 2022. This represents 20% of the total value of the live research grants and 66% of our budgeted amount (£600k) for the year.

For an overview of our research income for 2022 please refer to our research summary for 2022 in the Appendix.

2. Dissemination and Education Activities

In 2022, OHE continued its dissemination and education activities through a combination of virtual and face-to-face events. As described in the research summary attached:

- On the 6th of October, Prof. Eddy Van Doorslaer, the Professor of Health Economics at Erasmus University Rotterdam, presented the OHE's first-ever hybrid OHE annual lecture at the Royal College of Physicians, titled "*Universal Health Coverage: more than just old wine in a new bottle?*". The overall attendance was ninety-five.
- OHE organised five brown-bag and lunchtime seminars.
- Staff presented at conferences, gave invited speeches, and/or participated in workshops. The number of presentations for 2022 was seventy-five.

3. Events

OHE's is committed to organise events and present our research in different formats. Events encourage debate and facilitate decision-making, meeting another of our charity objects. This year, besides the annual lecture and the 60th Anniversary events, OHE held an event to deliver the award of the OHE Innovation Policy Prize. OHE also organized six webinars (four for free and two sponsored), two masterclasses, and one lunchtime seminar.

4. Summary of impact

As summarised in the research report, there are a few projects that we consider had an impact above the average: AMR, Digital Health and Precision Oncology.

For the AMR, an OHE study on the [Transferable Exclusivity Extension](#) for AMR was published by EFPIA, which gave it a wide audience and impact. Additionally, OHE contributed to NICE's AMR pilot by supporting Pfizer in their negotiations with NHS England, publishing a blog series on the pilot for the wider audience. OHE also held a webinar in which NHS England and NICE participated. The webinar was held virtually and more than 150 attendees from different countries registered.

For Digital Health, OHE's received a lot of attention for providing the cost-effectiveness analysis of *Sleepio*, [NICE's first digital health positive decision](#). In this area, OHE was commissioned by HITAP, the Thai HTA agency, to lead a study on the regulation of digital health in the UK. OHE's work along with other

countries' studies are to inform the future of the Digital Health landscape in Thailand.

Finally, OHE's research on precision oncology was published in [Nature Medicine](#) and [Healthcare](#) and presented at multiple conferences, including [ISPOR](#) and a keynote address at a Precision Oncology Forum in Berlin in December by Lotte Steuten.

Another measure of impact is OHE's presence on social media. OHE continued to have substantial activity on social media throughout 2022. In summary, we published forty regular blogs online and achieved the following social media presence:

- Number of publication downloads: 12,535
- Number of website visits: 148,863
- LinkedIn followers: 8,032
- Twitter followers: 5,572

Pro bono activities: The research summary for 2022 in the Appendix shows that OHE staff continue to engage in a wide variety of *pro bono* activities, including membership on advisory panels, boards and committees and eleven associations with universities. Pro bono activities also include prestigious think tanks, participation on advisory boards, serving on committees, supervising student placements, examining doctoral research theses, and undertaking reviews.

Financial review

Financial structure


In 2022, OHE remained an organisation undertaking research and related activities according to its charitable objects and status of independent research organisation.

OHE owns the sole share in *OHE Consulting Limited* with the purpose of enabling OHE to:

- **employ** a larger staff team than would be possible using research income alone
- allow staff to **gain knowledge**, skills and experience undertaking consulting projects that can be carried across into research and research-related projects
- Most importantly, **invest** the profits generated from consultancy work as Gift Aided to OHE, to fund OHE's activities in 2022.

In 2022, OHE employed an average of thirty-five staff of which 28 were researchers. Research staff are organised in four research themes as deployed in the diagram below.

In July of 2022, OHE implemented a structural reorganisation of its staff. Besides the four research themes, an OHE Graduate School and an OHE Academy were launched under the supervision of the Chief Research Officer and Head of Education. Additionally, a Director of Marketing and Communications and a Director of External Affairs were hired.



Financial performance in 2022

The financial statements of OHE comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts following The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) ("Charities SORP FRS 102").

OHE's consolidated turnover (i.e., combining both OHE and OHE Consulting Limited) in 2022 was **£4.38m**. The expenditure totalled **£4.07m**, leaving a net income of £313,223.

Of the £4.07m expenditure, staff costs in 2022 amounted to **£2.74m**, i.e., 67%.

Support services for the consolidated businesses accounted for **£0.41m**.

The consolidated accounts for OHE are included as an Annex to this report.

Sources of funding

The sources of funding for OHE are summarised below. The financial reports attached provide more details about OHE income and expenditure.

The consolidated income of £4.38m comprises:

	£000
Donations – research grants	300
Income from charitable (research) activities	551
Interest	1.4
Total research income	851
OHE Consulting Income	3,533
Total Income	4,386

Donations are from the ABPI and are for two distinct purposes:


	£000
Support for core research activities	300
Grant towards financing of support activities	405
Total	705

Income from charitable (research) activities came from several sources. Major research projects and funders included: Health Foundation, the Cancer Research UK, EuroQol Research Foundation

Structure, governance, and management in 2022

Figure 1 reflects the OHE governance structure by the end of 2022. At the top of the structure sits the OHE Board of Trustees. The Board is supported by the **Policy Committee** and the **Research Committee**. The Policy Committee's purpose is to advise OHE on engaging with policymaking and ensuring that OHE meets its Charitable Objects in this respect. OHE's work has been informing health care and pharmaceutical decision-makers and healthcare payers for decades, building its reputation on producing independent, academically strong research. Instead, the Research Committee guides OHE on research methods, oversees the core research grant programme, and ensures the quality and independence of OHE's research output. Thus, this committee ultimately assures the OHE Board of Directors that OHE's research meets its charitable objectives.

Figure 1: Organigram by the end of 2022



Epilogue

In sum, the year 2022 was a very important for OHE as a charity. OHE's educational mission was expanded and strengthened by the creation of an OHE Graduate School and an OHE Academy with the sole purpose of educating and disseminating health economics and promote evidence-based health policy making.

In 2023, this trend has been consolidated.

APPENDIX: 2022 Research Summary

1. Core-funded projects

Economics of innovation

Project	Summary	Investigators	Update on progress
Option Pricing (new 2022)	The use of real options in relation to pharmaceutical pricing has been promoted by the ISPOR Special Task Force on US Value Assessment Frameworks. How it can be calculated and used by payers in a way that avoids double-counting and rewards/targets investment appropriately is still being thought about. This core research project aims to move that thinking forwards via two invited editorials. The first is for <i>Value in Health</i> and will review a paper to be published. It will focus on whether payers should pay for option value. The second is for <i>Vaccine</i> . It will argue for payers being willing to add an option value to vaccine prices if this enables manufacturing capacity to be switched for use in a pandemic to be maintained.	Adrian Towse	The write up is ongoing.
The role of Product Development Partnerships (PDPs) in Pharmaceutical Innovation: are they complements or substitutes for private investment?	<p>Product Development Partnerships (PDPs) are a rational economic response to the lack of incentives for private pharmaceutical R&D in areas of low expected returns but high unmet need (e.g., neglected tropical and infectious diseases, rare diseases). In this research, we examine:</p> <ul style="list-style-type: none"> i) how different types of PDPs are associated with the likelihood of product approval, i.e., successful pharmaceutical innovation, ii) whether some types of PDPs stimulate drug development effectively in the early stages of innovation, iii) how do public and private pharmaceutical R&D investments relate to each other? Are they complements (i.e., public/donor investment incentivises private R&D in crucial areas?) or are they substitutes (i.e., public funding displaces private investment, especially in areas of low economic incentives for private investment, iv) whether the role of the PDPs in pharmaceutical innovation, as complement or substitute, varies across different therapeutic areas, phases of the drug development and/or archetypes of health technologies (i.e., vaccines, new chemical entities, biologics, diagnostics)? <p>The experience of the last decades shows that PDPs positively influence pharmaceutical innovation and access to treatment around the world by bringing new</p>	Dimitrios Kourouklis, Mikel Berdud, Mireia Jofre-Bonet, Adrian Towse, Margaret Kyle (MINES ParisTech)	The paper has been published in <i>Applied Economic Letters</i> , and the project has been closed. As previously reported, in 2021 it also presented as a paper at iHEA and ISPOR Europe.

	products to the market where they are needed. Literature has theoretically and empirically explored whether public funding for R&D is complementary or substitutive to private funding. Although findings point out that direct government funding heavily influences the development of drugs, the evidence is non-conclusive in determining its complementary or substitutive nature. Thus, a better understanding of the relationship between private and public investment in pharmaceutical R&D is necessary to identify the conditions under which public and private efforts complement each other optimally for the common good. "		
The impact of R&D tax credits on pharmaceutical innovation in the UK	<p>This project studies the impact of the Research and Development Expenditure Credit (RDEC) scheme, designed to increase support for private research and development through tax credits. The use of R&D tax credits is a well-recognised method for providing a fiscal incentive that will reduce the cost of R&D; however, the literature has struggled to properly estimate its effect on true innovation. In general, studies fail to provide estimates on meaningful innovation and focusing on R&D spending means that results are highly subject to varying efficiencies between firms.</p> <p>This research considers the treatment group to be the UK and the treatment itself to be the implementation of the RDEC in 2013. However, the problem with causal inference in this kind of study is that the counterfactual is unobservable and finding another country that can act as a suitable control may not be possible. The Synthetic Control Method (SCM), developed by Abadie and Gardeazabal (2003), will allow us to estimate the treatment effect by comparing outcomes observed in the UK to a weighted convex combination of the same outcome variables measured in other similar countries. By evaluating the effectiveness of the RDEC policy in incentivising innovation, we can help countries such as the UK evaluate its importance and therefore inform essential cost-benefit analysis. Understanding the impact of the RDEC can also help countries like the UK assess its potential use in driving innovation in specific areas of health care that need it, such as genetic research, vaccinations, or other disease areas that face scarcity in therapeutic options.</p>	Edward Oliver, Dimitrios Kourouklis Mireia Jofre-Bonet	The paper is under review at <i>Research Policy</i> . It was presented at AHEA 2022.
R&D competition & diffusion of innovation in the EU: the case of Hepatitis C	<p>"The project seeks publication in a peer-reviewed journal of previous OHE Research work. We assessed the impact of (i) intellectual property protection incentives for R&D, (ii) market competition, and (iii) other factors, including healthcare policies, on access to Direct Acting Antivirals (DAAs) in Europe.</p> <p>The study combined an economic framework with analyses of market shares and uptake of DAAs and interviews with relevant stakeholders of six European Countries (France, Germany, Italy, Portugal, Spain and the UK) to assess the degree and nature of market competition for DAAs between 2014Q1 and 2017Q2. The theoretical models</p>	Mikel Berdud, Martina Garau, Margherita Neri, Phill O'Neill, Chris Sampson, Adrian Towse	Published as an OHE Research Paper. Journal write-up has been completed and the article was rejected from <i>Applied Health Economics and Health Research</i> . A

	<p>show that current R&D incentives based on IP protection in the EU can encourage in-patent competition. The uptake analyses showed that competition within the DAA class was intense in European markets soon after the launch of the first-in-class treatment. Evidence from our interviews suggested that in-class competition improved access and uptake and provided bargaining power to country payers. IP incentives for R&D may have encouraged a high degree of in-class competition among DAAs. The in-class competition positively impacted the uptake and adoption of DAAs in the top 5 European countries.</p>		<p>resubmission is planned.</p>
<p>Value of Innovative Medicines: The Case of Risperidone and Second-generation Antipsychotics?</p>	<p>The project seeks publication in a peer-review journal of previous OHE Research work. The present work aims to assess the life-cycle value of innovative medicines based on the example of Second-Generation Antipsychotics (SGA). Using risperidone as representative of the SGA class and comparing it to haloperidol – its counterpart from the First-Generation Antipsychotics (FGA) – this research estimates a proxy of the life-cycle cost-effectiveness of the SGA class against FGA class in incremental terms. It also estimates the absolute social value-added, measured by the sum of the consumer and producer surpluses.</p> <p>This project provides evidence of the long-run cost-effectiveness of innovative medicines in Sweden and the UK. This research informs policy decision-makers, payers, and HTA bodies about the importance of balancing the view that cost per QALY estimates at launch alone are enough to guide access decisions with long-run estimates of the value added by drugs throughout their entire life cycle.</p>	<p>Mikel Berdud, Adrian Towse, Niklas Wallin-Bernhardsson (IHE), Bernarda Zamora (independent), Peter Lindgren (IHE)</p>	<p>Published as an OHE Research Paper. Manuscript submitted to Value in Health. Revisions have also been submitted, and the authors are awaiting the decision.</p>
<p>Setting out the conditions in which risk-sharing schemes improve value for money</p>	<p>Regulators have increasingly emphasised approving potentially important treatments rapidly, notably through accelerated access schemes. As a consequence, there is a challenge for payers. Products are launched with less evidence, creating greater uncertainty about their relative effectiveness and value for money. Previous research focusing on the use of Vol approaches to conditional approval has looked only at the case for only in-research (OIR) or only with research (OWR) and not considered risk sharing as an additional option. The research question is, “when does risk-sharing improve outcomes for patients and the health system –in terms of making cost-effective treatments available when they otherwise would be delayed or not made available at all? Specifically, the results should be robust to situations in which there are differences of opinion between manufacturers and payers around the value of new technology to the health system, which are unbiased (i.e., not negotiation posturing).</p>	<p>Adrian Towse, Liz Fenwick (Open Health)</p>	<p>Journal article preparation is ongoing. As previously reported, the research was used in OHE Masterclass on adaptive pathways in September 2021.</p>

Value, affordability, and decision-making

Project		Investigators	Update on progress
<p>NICE Methods Review blogs (inew 2022)</p>	<p>OHE responded to two NICE consultations during the review process (Dec 2020, Nov 2021), funded as core research. Following the second consultation, we prepared a series of blogs on the new NICE health technology evaluation manual. Each post provided a critical discussion on key topics, including the expected implications of the changes (or lack thereof) in the manual, what was still missing, and what further research was needed. The blogs went online between February and April (2022). The blogs are:</p> <p>New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)</p> <p>To Hell with the 3L! NICE's Missed Opportunity to Upgrade Health Outcome Measurement</p> <p>Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet?</p> <p>The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed?</p> <p>NICE's severity modifier: a step in the right direction, but still a long way to go</p> <p>Let's talk about (health) inequalities</p>	<p>Patricia Cubi-Molla, David Mott, Eleanor Bell, Edward Oliver, Martina Garau</p>	<p>6 blogs were published, one of which has received over 200 views to date. The project has been closed.</p>
<p>Landscape analysis of country processes and stakeholder mapping for digital health technologies in England (new 2022)</p>	<p>HITAP sought OHE to conduct a landscape analysis consisting of a review of the legal frameworks and processes involved in conducting an HTA of digital health technologies in England, and relevant stakeholders involved in the process, highlighting key issues and lessons learned in the U.K.</p> <p>OHE focussed on the regulatory framework for digital health, the process for assessing or improving digital literacy in the population, the HTA process and methods for digital health technologies. OHE further provided a mapping of relevant stakeholders, examples of a digital health technology that the national healthcare provider has reimbursed and provided lessons learned.</p>	<p>Simon Brassel, Priscila Radu, Martina Garau, Eleanor Bell</p>	<p>OHE provided HITAP with the report in June 2022.</p> <p>Eleanor Bell will present a related poster at the European Digital Medicine Conference in Luxembourg.</p> <p>Simon Brassel will contribute to a related panel session at HTAsiaLink 2022 in Thailand.</p> <p>HITAP's plan is to publish a report drawing from the landscape analyses of</p>

			five countries to inform the future Digital Health landscape in Thailand. OHE will be co-authors of said report.
ViH re-submission of Health System Capacity Value Publication (new 2022)	<p>In December 2021, OHE completed a project funded by the ABPI vaccines group, submitting a paper to conceptualise the health system pressure of vaccines to the journal <i>Value in Health</i>.</p> <p>In February 2022, OHE was invited to revise and resubmit the paper following the feedback from two peer reviewers.</p> <p>The paper made policymakers aware that, in addition to preventing the outcome of interest, vaccines and other preventative health technologies deliver value in maintaining regular healthcare services and clearing the pent-up demand from the pandemic. Therefore, health system capacity value should be a key-value element in health technology assessment. Existing and potential future vaccination programs deliver more value than hitherto quantified.</p>	Simon Brassel,	The paper was accepted by <i>Value in Health</i> and is currently in press. The project has been closed.
Are QALY gains an appropriate measure of the societal value of end-of-life care?	<p>Advocates argue that the QALY-maximisation framework systematically undervalues end-of-life care relative to curative interventions in a number of respects. First, as the primary objective of end-of-life care is not to extend survival, they suggest that it is inappropriate to consider a time element in its evaluation as in curative interventions. Second, they object to the principle that the value of a year of life is determined solely by the health-related quality of that year. This objection is based on the notion that some periods of time may be more valuable than others, including milestone moments such as weddings or birthdays or in this context, the time before death. Third, they argue that the currently constructed QALY neglects important health-related quality-of-life dimensions. These objections are collectively referred to as the 'QALY problem'.</p> <p>To test these objections, we conducted a stated preference elicitation to understand public preferences for different end-of-life care scenarios, focusing on the relative importance of survival, conventional health dimensions (especially physical symptoms and anxiety), and less-conventional dimensions such as family relations, dignity, and sense of control.</p> <p>We found that although a minority of respondents strongly prioritised survival gains, most gave substantially more weight to non-health aspects. We suggest that these results argue for a broader conception of value in the context of end-of-life care.</p>	Chris Skedgel	The findings have been written up as a manuscript, to be submitted for consideration to a peer-reviewed journal.

<p>ICER pricing, bargaining, and Cost-Effectiveness Thresholds (CETs)</p>	<p>The project seeks publication in a peer-review journal of previous OHE consulting work for Roche. A novel supply and demand model of pharmaceutical markets is presented to analyse the relationship between the value of the CET and the distribution of new medicines' health and economic value between consumers (payers) and developers (life science industry). The model incorporates a bargaining process and bargaining power distributed between the payer and the developers, which impacts the distribution of the health and economic value of new medicines between the two parties. One of the paper's key findings is that, with a sufficiently large payer's bargaining power, an efficient CET value could be higher than the supply-side CET used for decision making. This result has important policy implications. For example, if market access for innovative medicines is based in HTA using CETs defined by the health system opportunity costs, there would be circumstances under which some cost-effective (in the long run) medicines would not be granted. This would result in reimbursement, and incentives for investing in future innovation would be undermined. This would produce inefficient resource allocation in the present, leading to not optimal innovation production in the future.</p>	<p>Mikel Berdud, Adrian Towse</p>	<p>The manuscript has been submitted to Frontiers in health services. Waiting for the first decision</p>
<p>Digital Health Economics</p>	<p>More and more digital health technologies are entering the market and being adopted by health systems worldwide. The application of health economics differs across the spectrum of health technologies. This is, at least in part, the result of characteristic differences between pharmaceuticals, medical devices and digital health technologies (DHTs) that affect related innovation, commercialisation, evaluation and application within health systems. At present, there is no overarching framework to conceptualise how the characteristics of DHTs may affect the way these technologies are developed, launched, assessed, priced, reimbursed, and distributed. The proposed research will fill this gap by linking the summarised technology differences to their respective implication for the health economics field. The research will take the form of a narrative literature review to be published as an OHE Briefing.</p>	<p>Simon Brassel, Eleanor Bell, Martina Garau</p>	<p>The literature review is ongoing. As previously reported, Initial findings were presented at an ISPOR Europe workshop in December 2021.</p>
<p>Value of life and health</p>	<p>This paper follows up on a research project with Amgen and will be submitted for publication in 2021. Government departments regularly monetise the value of a life for the purposes of informing resource allocation. In many countries, guidance documents set out the manner in which economic evaluation should be conducted, often specifying the precise values to be used for different impacts. However, we find different values of life and health are used in analyses by departments despite commonality in outcomes, giving rise to potential inconsistencies in decision-making and considering trade-offs within a broader public sector spending budget. Our research intends to provide some evidence to better inform the political process and</p>	<p>Patricia Cubi-Molla, Martina Garau, David Mott, Nadine Henderson</p>	<p>The paper received a reject and resubmit from Cost Effectiveness and Resource Allocation. It will be resubmitted in 2022.</p>

	raise a number of important issues on assessing the value of public expenditure across different sectors. Our targeted literature review aimed to identify thresholds, explicitly or implicitly, as observed in government-related publications, which we understand to represent the government's willingness to pay for health gain.		
--	--	--	--

Policy, organisation, and incentives in health systems

Project	Summary	Investigators	Update on progress
Primary Care Valued Output (new 2022)	This project aims to revise and resubmit a manuscript summarising the development of a framework to measure the valued output of primary care in England. This manuscript represents the second contribution of the Health Foundation-funded Efficiency Research Programme grant.	Margherita Neri, Patricia Cubi-Molla, Graham Cookson	This core research project started in September 2022. The planned re-submission is by the end of 2022.
The Effect of Distance on Accident and Emergency Department Demand (new 2022)	When individuals choose to attend a hospital accident and emergency department (AED), they must incur both the time and financial costs of travel, which are both likely to increase with distance. The aim of this research is to quantify the relationship between travel distance and emergency department demand using area-level regression analysis. This research will also explore the extent to which the role distance travelled plays in the decision to attend an AED is dependent on the severity of the individual's condition. This work builds upon research conducted by Sian Besley for her MSc Health Economics dissertation and the findings of this project will be submitted to a health economics journal.	Sian Besley	All data analysis is complete and journal article write-up is ongoing.
Healthcare budget design across emerging and developed countries (new 2022)	The Aspen Institute and Pfizer are holding a roundtable for former health and finance experts from Governments around the world. This project aimed to produce a background paper as a preface to the roundtable dialogue. The background paper covers how emerging and developed countries have approached health care budgets in the past, and how COVID-19 has changed (or might change) this going forward. The background paper was prepared for an initial virtual roundtable in April 2022, with adjustments made for the in-person roundtable in October 2022.	Hannah Schirmmacher, Mireia Jofre-Bonet	The background paper was produced, and the research project has been closed.

<p>The impact of Egypt's health sector reform program on family planning and maternal and child health</p>	<p>This project aims to estimate the impact of Egypt's health sector reform program (HSRP) on family planning and maternal and child health in Egypt during the years 2000-2008. The paper highlights the impact of the HSRP on antenatal care, delivery care, women's access to health care and child morbidity prevalence. The primary data source used to assess the impact of the HSRP in Egypt on maternal and child health was a cross-sectional demographic and health survey, conducted in 2000, 2005 and 2008, the Egypt Demographic and Health Survey (EDHS).</p>	<p>Mireia Jofre-Bonet, Patricia Cubi-Molla, (Amira El-Shal)</p>	<p>Two papers have been published, 'Are user fees in health care always evil? Evidence from family planning, maternal, and child health services' (<i>Econ Analysis and Policy</i>) and 'Accreditation as a quality-improving policy tool: family planning, maternal health, and child health in Egypt' (<i>EJHE</i>) A third paper ('Discontinuation of performance-based financing in primary health care: Impact on family planning and maternal and child health') is under revision. A blog will follow the third publication.</p>
--	---	---	---

Measuring and valuing outcomes

Project	Summary	Investigators	Update on progress
<p>Accounting for preference heterogeneity in discrete-choice experiments: A survey of the state of practice</p>	<p>This project relates to a collaboration with the ISPOR Health Preference Research Special Interest Group (SIG). The SIG noted that, while ISPOR and others have published multiple guidelines concerned with the design, analysis, and reporting of DCEs, little consideration has been given to the topic of preference heterogeneity. Therefore, the SIG formed a working group that aimed to describe the status-quo in accounting for heterogeneity in preference data collected within a DCE.</p>	<p>David Mott, ISPOR Health Preference Research SIG</p>	<p>The paper was published in <i>Value in Health</i> in May 2022. The project has been closed.</p>
<p>Blocking in the design of discrete choice experiments:</p>	<p>This project relates to a collaboration with the ISPOR Health Preference Research Special Interest Group (SIG). The SIG's earlier project on preference heterogeneity (see "Accounting for preference heterogeneity in discrete-choice experiments: A survey of the state of practice") produced a literature review dataset containing hundreds of DCE</p>	<p>David Mott, Nadine Henderson</p>	<p>The literature review has been completed</p>

a review of current practice	studies. As an offshoot of the earlier project, a smaller project team was put together to use and build upon the existing dataset to explore blocking in experimental designs for DCEs in health. Little guidance exists relating to blocking, and the results of this subsequent review will be written up as a short manuscript reflecting on current practice.		and the write-up is ongoing.
------------------------------	--	--	------------------------------

2. Research grants and projects

The table below includes funded research projects that have been won since January 2022 (including extensions to existing projects) and proposals that are currently in preparation, under review, or yet to be contracted. We weigh each proposal by the expected probability of winning it to estimate our potential research income.

	Funder	Project Title	Research Theme	Status	External collaborators	Net value to OHE
1	EuroQol Research Foundation	This or that dead?	MVO	Won (April 2022)		£4,481
2	EuroQol Research Foundation	Exploring the use of the OPUF tool for valuing EQ-5D-Y-3L	MVO	Won (Jan 2022)	Paul Schneider (Uni of Sheffield), Koonal Shah (NICE), Nancy Devlin (Uni of Melbourne)	£63,010
3	EuroQol Research Foundation	Extension of Development and Testing of a Hearing Bolt-on	MVO	Won (Mar 2022)	Rebecca Addo, University of Technology Sydney, Phil Haywood, University of Technology Sydney, Brendan Mulhern, University of Technology Sydney	£11,610
4	High Flow Therapy UK	High Flow Therapy Post AECOPD	VADM	Won (June 2022)		£74,158
5	LSE Dept Health Policy	Healthcare Resilience Index	POIHS	Won (January 2022)	LSE Department of Health Policy	£79,054

6	MINES ParisTech	Healthcare budget design across emerging and developed countries	POIHS	Won (Aug 2022)		£8,186
7	Pfizer	Educational Course Vaccines	VADM	Won (Jan 2022)		£255,429
8	Acute Leukaemia Advocates Network	Patient preferences for Leukaemia treatments (extension for phases 5 and 6)	MVO	Subject to contract	Steering group members	£73,789
9	Acute Leukaemia Advocates Network	Patient preferences for Leukaemia treatments (country extension)	MVO	Won (Dec 2022)	Steering group members	£90,096
10	Cancer Research UK	Oncology Target Product Profiles	EOI	Won (Dec 2022)		£50,722
11	Center for Economic and Social Research at the University of Southern California	Sustainable financing models to support the development of and access to novel antibiotics in Singapore	VADM/EOI	Won (Nov 2022)		£18,844
12	European Commission	EU Horizon 2022 HI-PRIX project	EOI	Subject to contract	Imperial College London Nova School of Business & Economics I3h Institute Université libre de Bruxelles (ULB) Universidad Carlos III de Madrid (previously EC) Erasmus University Rotterdam AIHTA (Austrian Institute for HTA) Infarmed (National Authority of Medicines and Health Products) Valleta group Vilnius university	£354,000

					Ideas&SolutionsParis School of Economics et Université of Paris 1 Bocconi University (leading) LSE-Health Policy Andalusian School of Public Health Hamburg University Hospital Clinic of Barcelona	
13	EuroQol Research Foundation	Estimating EQ-5D-Y-3L value sets in UK	MVO	Subject to contract	Oliver Rivero-Arias, University of Oxford Donna Rowen, University of Sheffield Koonal Shah, NICE Juan Manuel Ramos- Goñi, Maths in Health	£7,650
14	EuroQol Research Foundation	Bolt-on conceptual project	MVO	Subject to contract		£25,739
15	EuroQol Research Foundation		MVO	Revised/resubmi tted	Rebecca Addo, University of Technology Sydney Phil Haywood, University of Technology Sydney Brendan Mulhern, University of Technology Sydney	£34,688
16	University College London	UCL Value Based Healthcare Executive Education course	EOI	Commitment		0
		TOTAL INCOME				£1,151,546

Research themes: Eoi = Economics of Innovation; MVO = Measuring and Valuing Outcomes; POIHIS = Policy, Organisation, and Incentives in Health Systems; VADM = Value, Affordability, and Decision Making. Prob. = probability. Prob. Adj. Value = probability adjusted value.

3. Research output 2022

PUBLICATIONS

We present our publications in three main groups: publications in external peer-reviewed journals; publications on OHE's website (peer-reviewed by the OHE reviewing process); OHE reports; books and chapters; and working papers in external institutions.

EXTERNAL PEER-REVIEWED JOURNAL ARTICLES

For external peer-reviewed journal articles, we provide information on the sources of financial support, number of citations, and number of views and downloads. We also provide the journals 2 year and 5 year impact factors.

NO.	JOURNAL REFERENCE	SOURCES OF FINANCIAL SUPPORT?	NUMBER OF CITATIONS (AS OF DEC 2022)	NUMBER OF VIEWS AND DOWNLOADS (AS OF OCT 2022)	2 YEAR IMPACT FACTOR (WEB OF SCIENCE 2021)	5 YEAR IMPACT FACTOR (WEB OF SCIENCE 2021)	
1	Bell, E., Brassel, S., Oliver, E., Schirmacher, H., Arnetorp, S., Berg, K., Darroch-Thompson, D., Pohja-Hutchison, P., Mungall, B., Carroll, S., Postma, M. and Steuten, L. , 2022. Estimates of the Global Burden of COVID-19 and the Value of Broad and Equitable Access to COVID-19 Vaccines. <i>Vaccines</i> . DOI: 10.3390/vaccines10081320	Consulting (AstraZeneca)	3		4.961	5.325	
2	Bell, E., Neri, M., & Steuten, L. 2022. Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward. <i>Applied Health Economics and health policy</i> . DOI: 10.1007/s40258-021-00683	Funded Research (Pfizer)	10		3.686	3.674	

NO.	JOURNAL REFERENCE	SOURCES OF FINANCIAL SUPPORT?	NUMBER OF CITATIONS (AS OF DEC 2022)	NUMBER OF VIEWS AND DOWNLOADS (AS OF OCT 2022)	2 YEAR IMPACT FACTOR (WEB OF SCIENCE 2021)	5 YEAR IMPACT FACTOR (WEB OF SCIENCE 2021)
3	Brassel, S., Neri, M., Schirmacher, H., Steuten, L., 2022. The Value of Vaccines in Maintaining Health System Capacity in England. <i>Value in Health</i> . DOI: 10.1016/j.jval.2022.06.018	Consulting (ABPI)	2		5.101	6.747
4	El-Shal, A., Cubi-Molla, P. and Jofre-Bonet, M., 2022. Discontinuation of performance-based financing in primary health care: impact on family planning and maternal and child health. <i>International Journal of Health Economics and Management</i> . DOI: 10.1007/s10754-022-09333-w	None	0		1.837	1.731
5	Fernandes, S., Pinto, M., Barros, L., Lopes Moreira, M.E., Velho Barreto de Araújo, T., Maciel Lyra, T., Valongueiro, S., Jofre-Bonet, M., Kuper, H. 2022. The economic burden of Congenital Zika Syndrome in Brazil: overview at 5 and 10 years. <i>BMJ Global Health</i> . DOI: 10.1136/bmjgh-2022-008784	None	0		8.056	7.901
6	Hernandez-Villafuerte, K., Zamora, B., Feng, Y. Towse, A. et al. 2022. Estimating health system opportunity costs: the role of non-linearities and inefficiency. <i>Cost Effectiveness and Resource Allocation</i> . DOI: 10.1186/s12962-022-00391	ABPI	0		2.803	2.975
7	Horgan, D., Borisch, B., Cattaneo, I., Caulfield, M., Chiti, A., Chomienne, C., Cole, A., et al., 2022. Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare. <i>International Journal of Environmental Research and Public Health</i> . DOI: 10.3390/ijerph19031674		3		4.614	4.799
8	Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., et al as part of the CHEERS 2022 ISPOR Good Research Practices Task Force 2022., Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic	None	190		5.271	4.133

NO.	JOURNAL REFERENCE	SOURCES OF FINANCIAL SUPPORT?	NUMBER OF CITATIONS (AS OF DEC 2022)	NUMBER OF VIEWS AND DOWNLOADS (AS OF OCT 2022)	2 YEAR IMPACT FACTOR (WEB OF SCIENCE 2021)	5 YEAR IMPACT FACTOR (WEB OF SCIENCE 2021)	
	evaluations. <i>European Journal of Health Economics</i> . (Epub ahead of print). DOI: 10.1007/s10198-021-01426-6 .						
9	Husereau, D.; Steuten, L. ; Muthu, V.; Thomas, D.M.; Spinner, D.S.; Ivany, C.; Mengel, M.; Sheffield, B.; Yip, S.; Jacobs, P.; Sullivan, T. 2022. Effective and Efficient Delivery of Genome-Based Testing- What Conditions Are Necessary for Health System Readiness? <i>Healthcare</i> 2022. DOI: 10.3390/healthcare10102086	Amgen Canada, Inc.; AstraZeneca Canada Inc.; Eli Lilly Canada, Inc.; GSK Canada Inc.; Hoffmann-La Roche Canada, Inc. (Diagnostics Division); Janssen (J&J) Canada Inc.; Pfizer Canada Inc.; Thermo Fisher Scientific (Canada)	0		3.16	3.46	
10	Kourouklis, D., Berdud, M., Jofre-Bonet, M. and Towse, A. , 2022. Alternative funding models for medical innovation: the role of product development	Core research grant	0		1.287	1.215	

NO.	JOURNAL REFERENCE	SOURCES OF FINANCIAL SUPPORT?	NUMBER OF CITATIONS (AS OF DEC 2022)	NUMBER OF VIEWS AND DOWNLOADS (AS OF OCT 2022)	2 YEAR IMPACT FACTOR (WEB OF SCIENCE 2021)	5 YEAR IMPACT FACTOR (WEB OF SCIENCE 2021)	
	partnerships in product innovation for infectious diseases. <i>Applied Economics Letters</i> . DOI: 10.1080/13504851.2022.2095335						
11	Kourouklis, D. and Gandjour, A., 2022. Pharmaceutical Spending and Early-Stage Innovation in EU countries. <i>Industry and Innovation</i> . DOI: 10.1080/13662716.2021.2021864	None	0		3.819	4.674	
12	Kourouklis, D., Sampson, C., Berdud, M. and Skedgel, C. 2022. <u>Building Cost-Effectiveness Thresholds for the Future</u> . <i>Value & Outcomes Spotlight</i> .	Consulting (ABPI)			N/A	N/A	
13	Kreimeier, S., Mott, D. , Ludwig, K., Greiner, W., & IMPACT HTA HRQoL Group. 2022. EQ-5D-Y Value Set for Germany. <i>Economics</i> . DOI: 10.1007/s40273-022-01143-9	Funded research (EuroQol)	13		4.558	5.195	
14	Mateo, J., Steuten, L. , Aftimos, P., André, F., Davies, M., Garralda, E., Geissler, J., Huserreau, D., Martinez-Lopez, I., Normanno, N., Reis-Filho, J., Stefani, S., Thomas, D., Westphalen, B., & Voest, E. 2022. Delivering Precision Oncology to Patients with Cancer. <i>Nature Medicine</i> . DOI: 10.1038/s41591-022-01717-2	None	53		87.241	68.31	
15	Mott, D. J. , Devlin, N. J., Kreimeier, S., Norman, R., Shah, K. K., & Rivero-Arias, O. 2022. Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L. <i>PharmacoEconomics</i> . DOI: 10.1007/s40273-022-01214-x	Funded research (EuroQol)	1		4.579	5.205	
16	Mott, D. , Ternent, L., & Vale, L. 2022. Do preferences differ based on respondent experience of a health issue and its treatment? A case study using a public health	Funded research	0		5.271	4.133	

NO.	JOURNAL REFERENCE	SOURCES OF FINANCIAL SUPPORT?	NUMBER OF CITATIONS (AS OF DEC 2022)	NUMBER OF VIEWS AND DOWNLOADS (AS OF OCT 2022)	2 YEAR IMPACT FACTOR (WEB OF SCIENCE 2021)	5 YEAR IMPACT FACTOR (WEB OF SCIENCE 2021)	
	intervention. <i>The European Journal of Health Economics</i> . DOI: 10.1007/s10198-022-01482-	(Health Foundation)					
17	Mulhern, B.J., Sampson, C. , Haywood, P., Addo, R., Page, K., Mott, D. , Shah, K., Janssen, M.F. and Herdman, M. , 2022. Criteria for Developing, Assessing and Selecting Candidate EQ-5D Bolt-Ons. <i>Quality of Life Research</i> . DOI: 10.1007/s11136-022-03138-7	Funded research (EuroQol)	1		3.44	4.388	
18	Pouwels, X.G.L.V., Sampson, C.J. , and Arnold, R.J.G., 2022. Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey. <i>Value in Health</i> . DOI: 10.1016/j.jval.2021.10.001	None	9		5.101	6.747	
19	Ramos-Goñi, J. M., Estévez-Carrillo, A., Rivero-Arias, O., Rowen, D., Mott, D. , Shah, K., & Oppe, M. 2022. Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences? <i>Value in Health</i> . DOI: 10.1016/j.jval.2022.03.001	Funded research (EuroQol)	5		5.101	6.747	
20	Rodes-Sanchez, M. , Spencer, J., Tantri, A., Mitrovich, R., Rachev, B., Sharma, I., Towse, A. , Steuten, L. 2022. Working Towards a Sustainable, Healthy Market for Vaccines: A Framework to Support Evidence-Based Policymaking. <i>Vaccine</i> 2022. DOI: 10.1016/j.vaccine.2022.05.054	Consulting (Merck Sharp & Dohme)	0		4.169	4.27	
21	Sampson, C. , Zamora, B., Watson, S., Cairns, J., Chalkidou, K., Cubi-Molla, P. , Devlin, N., García-Lorenzo, B., Hughes, D.A., Leech, A.A. and Towse, A., 2022. Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy. <i>Applied Health Economics and Health Policy</i> . DOI: 10.1007/s40258-022-00730-3	Consulting (ABPI)	3		3.686	3.674	

NO.	JOURNAL REFERENCE	SOURCES OF FINANCIAL SUPPORT?	NUMBER OF CITATIONS (AS OF DEC 2022)	NUMBER OF VIEWS AND DOWNLOADS (AS OF OCT 2022)	2 YEAR IMPACT FACTOR (WEB OF SCIENCE 2021)	5 YEAR IMPACT FACTOR (WEB OF SCIENCE 2021)
22	Sampson, C. NICE and the EQ-5D-5L: Ten Years Trouble. <i>PharmacoEconomics Open</i> 6, 5–8 (2022). https://doi.org/10.1007/s41669-021-00315-1	None	0		Not retrievable	Not retrievable
23	Skedgel, C., Henderson, N., Towse, A., Mott, D., & Green, C. 2022. Considering Severity in Health Technology Assessment: Can We Do Better? <i>Value in Health</i> . DOI: 10.1016/j.jval.2022.03.001	Consulting (Biogen)	2		5.101	6.747
24	Towse, A. 2022. Real Option Value: Should We Opt in or out? Commentary. <i>Value in Health</i> . DOI: 10.1016/j.jval.2022.09.004	Core research grant	0		5.101	6.747
25	Towse, A. and Silverman Bonfield, R. 2022. An Ambitious USG Advanced Commitment for Subscription-Based Purchasing of Novel Antimicrobials and Its Expected Return on Investment. <i>CGD Policy Paper 277</i> . Washington, DC: Center for Global Development. https://www.cgdev.org/publication/ambitious-usg-advanced-commitment-subscription-based-purchasing-novel-antimicrobials	None	1		N/A	N/A
26	Treibich, C., Bell, E. , Blanc, E., Lepine, A., 2022. From a drought to HIV: An analysis of the effect of droughts on transactional sex and sexually transmitted infections in Malawi. <i>SSM - Population Health</i> . DOI: 10.1016/j.ssmph.2022.101221	None	0		4.086	4.421
27	Vass, C., Boeri, M., Karim, S., Marshall, D., Craig, B., Ho, K.-A., Mott, D. , Ngorsuraches, S., Badawy, S. M., Mühlbacher, A., Gonzalez, J. M., & Heidenreich, S. 2022. Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report. <i>Value in Health</i> . DOI: 10.1016/j.jval.2022.01.012	Core research grant	9		5.101	6.747

NO.	JOURNAL REFERENCE	SOURCES OF FINANCIAL SUPPORT?	NUMBER OF CITATIONS (AS OF DEC 2022)	NUMBER OF VIEWS AND DOWNLOADS (AS OF OCT 2022)	2 YEAR IMPACT FACTOR (WEB OF SCIENCE 2021)	5 YEAR IMPACT FACTOR (WEB OF SCIENCE 2021)	
28	Yaman, F., Cubi-Molla, P. and Plagnol, A.C., 2022. Why do immigrants become less happy? Explanations for the decrease in life satisfaction of immigrants in Germany over time. <i>Migration Studies</i> . DOI: 10.1093/migration/mnac034	None	1		2.774	3.06	
29	Xie, RZ., Towse, A. , & Garrison, LPJr. 2022. Should We Pay for Scientific Knowledge Spillovers? The Underappreciated Value of "Failed" R&D Efforts. <i>International Journal of Technology Assessment in Health Care</i> . DOI: 10.1017/S0266462322000150	None	1		2.406	2.216	

OTHER EXTERNAL PUBLICATIONS

Book Chapter: **Cole, A.**, Handelin, B. and Cavalla, D., 2022. Chapter 12: Adapting Payers' and Producers' Incentives to Drug Repurposing. *In: Drug Repurposing*. DOI: [10.1039/9781839163401-00244](https://doi.org/10.1039/9781839163401-00244)

OHE PUBLICATIONS (PEER-REVIEWED OHE REPORTS)

PUBLICATION	SOURCES OF FINANCIAL SUPPORT	NUMBER OF DOWNLOADS
1. Besley, S., Henderson, N., Towse, A. & Cole, A. (2022) Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose? <i>OHE Consulting Report</i> .	Consultancy (Pfizer)	787
2. Cookson, G. and Hitch, J. (2022) Limitations of CBO's Simulation Model of New Drug Development as a Tool for Policymakers . <i>OHE Consulting Report</i> .	Consultancy (PhRMA)	107
3. Mott, D., Schirrmacher, H. & Garau, M. (2022) When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies . <i>OHE Consulting Report</i> .	Consultancy (PhRMA)	150
4. Brogaard, N., Abdul-Ghani, R., Bayle, A., Henderson, N., Bréant, A, and Steuten, L. (2022) Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies . <i>OHE Consulting Report</i> .	Consultancy (Roche)	409
5. Firth, I., Hitch, J., Henderson, N. & Cookson, C. (2022) Supporting the Era of Green Pharmaceuticals in the UK . <i>OHE Consulting Report</i> .	Consultancy (ABPI)	323
6. Towse A., Lothgren M., Bruce A, & Steuten L. (2022) Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies . <i>OHE Consulting Report</i> .	Consultancy (Amgen)	109
7. Brassel, S., Radu, P., Bell, E. and Garau, M. (2022) Navigating the Landscape <i>OHE Consulting Report</i>		405
8. Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques - OHE OHE research Report	This research study was commissioned and funded by Ferring	0

ADDITIONAL OHE PUBLICATIONS:

Jofre-Bonet, M. (2022) [2021 OHE Annual Report to the Charity Commission](#). *OHE Research Report*

OHE events

The OHE run an array of educational virtual and face to face events this year. These events include specialised webinars, roundtables, masterclasses and an annual lecture as well as a lunchtime seminar and some more informal brown-bag lunch seminars. This section provides an update on all of the OHE events held over 2022:

ROUNDTABLES

1. On the 24th February Eleanor Bell, Chris Skedgel and Adrian Towse, held a roundtable titled “Principles of a ‘fit for purpose’ Intellectual Property system in the biopharmaceutical industry”, sponsored by PhRMA; *A roundtable to discuss expert perspectives on the principles of a ‘fit for purpose’ Intellectual Property system for biopharmaceuticals.*
2. On the 25th April, David Mott held a roundtable titled: “Modelling carer quality of life”; *A roundtable to determine best practices in modelling carer quality of life, including whether or not bereavement effects should be considered in models.*
3. Chris Sampson and Edward Oliver held a roundtable titled: “The case for next-generation sequencing testing for lung cancer patients in Europe”. This took place over two meetings:
 - a. 12th July: *This meeting was used to gain cross-functional insights stakeholders on the status of NGS testing, barriers to uptake, and receive feedback on the outputs of our literature review*
 - b. 22nd September: *This was used to gain feedback on our proposed economic case for adoption of NGS testing in lung cancer and test our developed set of recommendations that will be included in the report and are designed to help drive uptake and widespread access to NGS testing in Europe*
4. On the 24th October Lotte Steuten and Simon Brassel held an OHE expert roundtable on best practice for AMR pull incentives. The roundtable was part of a project to articulate the problem of balancing a pull incentive mechanism with a value-assessment to non-experts; and to develop recommendations for how the delinked model could be developed to support a credible and affordable pull incentive while offering a value-based price for companies.
5. On the 6th December OHE hosted a roundtable which brought together international experts, to raise awareness of the issues and solutions associated with combination therapies. Prior to the roundtable, OHE, collaborating with Mickael Lothgren (Ipsen) and Andrew Bruce (Amgen), developed a solution-based paper, focused on an Outcome-based Value Attribution Framework for combination therapies. The roundtable resulted in a constructive discussion on the paper in the context of the current methodological and policy debate.

OHE LUNCHTIME and BROWN-BAG SEMINARS

1. In January, the OHE’s data visualisation team Isobel Firth, Nadine Henderson, Edward Oliver and Jake Hitch continued with their work of late 2021 with a recap on a brown bag seminar on “Data Visualisation”, where they provided insight on new data visualisation methods and practical ways to utilise new infographics templates.
2. On the 1st of February, Jake Hitch held a brown bag seminar titled “Intro to DCE Design Analysis”, where he presented measuring and valuing outcomes in an introduction to DCEs in patient preference research and beyond.
3. On the 21st of June, Peter Zweifel, an Emeritus of the University of Zurich, held the OHE’s first Hybrid lunchtime seminar titled “The Value of a QALY Towards the End of Life and its Determinants: Experimental Evidence.”

4. On the 12th of April, Isobel Firth and Simon Brassel held a brown bag seminar titled “Economics of AMR”, where they discussed the market failure of antibiotic development and how the OHE could spearhead its economic improvement.
5. On the 26th of July, Nadine Henderson held a brown bag titled “Medicines Tracker”, where she introduced the OHE-owned database that links several databases to track new medicines on their journey from EMA approval to their uptake in the UK, the market access dashboard and previous and current projects that had utilised the tool.

WEBINARS

1. On the 10th March, Chris Sampson presented the OHE Webinar “Do We need Health Economics”, where he discussed the fact that economic analysis has been central to decision-making in human health for decades. However, the same cannot be said for animal health.
2. On the 29th of September, the OHE hosted a webinar titled “Can we “Netflix” the broken antibiotics market? Building on the learnings from the NICE and NHS England pilot with a subscription-style approach to purchasing and evaluating antibiotics”. With various speakers, including the OHE’s Lotte Steuten, Nick Crabb (NICE), David Glover (NHS England) and Jason Gordon (HEOR Consulting) who, discussed their experiences with the evaluation and purchasing of antimicrobials and how to build on the learnings from the NICE NHS England.
3. On the 20th of October, the OHE webinar titled “Vaccines, Antivirals, Lockdowns & COVID-19: Learnings from the Pandemic” included the OHE’s Graham Cookson, Stuart Carroll, a senior health economist, epidemiologist, and health policy expert specialising in the NHS, Eddie Gray, who has spent forty years in the Pharmaceutical and Biotechnology sector, Nick Elliot, UK CEO of the new defence company Helsing, and other experts. This webinar brought together a collection of some leading decision-makers and eminent policymakers from the UK Government’s COVID-19 pandemic response through the world-leading vaccination programme and extensive antiviral rollout.
4. On the 7th December, the OHE Webinar title “Insights from 2022 & Emerging Issues for 2023” included OHE’s Graham Cookson, Lotte Steuten, Chris Skedgel, Amanda Cole and Mireia Jofre-Bonet. In our final webinar of the year, we are reflecting on the highlights and lowlights of the past year, which OHE research trends have had the biggest impact in 2022 and discussing which emerging issues we have identified for 2023.

SPONSORED WEBINARS

5. On the 22nd June the OHE hosted a Webinar sponsored by AstraZeneca which discussed collaborating on payment models to unlock the potential of multi-indication therapies.
6. On the 14th September OHE hosted a webinar commissioned by Pfizer entitled ‘Health Technology Assessment of Gene Therapies: Are Methods Fit for Purpose?’. This free to attend webinar was intended to be useful for a wide range of stakeholders that are interested in health technology assessment for gene therapies, including (but not limited to) payers, PAGs, regulators, health data scientists, academics, and industry.

MASTERCLASSES

1. On the 26th of May, OHE held its first hybrid OHE Masterclass titled “Severity in Value Assessment: From Principle to Practice”, where experts alongside the OHE’s Martina Garau, David Mott and Chris Skedgel discussed severity in HTA, measuring and integrating it in

decision making and considering severity in practice, including evidence from the decision-making framework in the Netherlands.

2. On the 22nd of June, the OHE hosted an AstraZeneca masterclass titled "Multi-Indication Therapies Masterclass". In this masterclass, the panel, including OHE's Graham Cookson and Amanda Cole presented viewers with a multi-stakeholder view on the need for and opportunities associated with payment models that recognise value at the indication-level, leveraging the findings of the [OHE Consensus Programme](#) and the experience of international experts.

OHE EXTERNAL EVENTS

OHE 60th Anniversary

1. On the 18th May the OHE celebrated their 60-year anniversary in Washington and presented a seminar considering 'the Past, Present, and Future of Health Economics' followed by a rooftop drinks reception with various ISPOR speakers and professionals in the field. The seminar covered three topics critically important to the evolution of health economics and its impact on pharmaceutical policy and practice over the past 60 years. For each section, we invited an external expert to provide their perspective followed by one of OHE's research leaders.
2. On the 16th June the OHE celebrated 60 years of pioneering research and invited some industry experts and thought leaders in the field to speak at the event, and join us in celebrating. The event took place at 4 Hamilton Place in London and about 140 attendants were served nibbles and drinks on the terrace with views over Hyde Park and listened to the commemorative speeches of Richard Murray, Chief Executive of The King's Fund; Graham Cookson, OHE's Chief Executive Officer; and Adrian Towse, former Director of OHE and now Emeritus Director.

OHE Annual Lecture 2022

On the 6th October, Prof. Eddy Van Doorslaer, the Professor of Health Economics at Erasmus University Rotterdam, presented the OHE's first-ever hybrid OHE annual lecture at the Royal College of Physicians, titled "Universal Health Coverage: more than just old wine in a new bottle?". In this lecture, he outlined that most countries seem to agree on the desirable goal of UHC: "Everyone—whether rich or poor—should get the care they need without suffering undue financial hardship as a result." What is much harder to provide, is solid comparative evidence of the extent to which countries' health systems manage to achieve this goal. Eddy referenced 2013 Adam Wagstaff, who argued in 2013 in a blog that UHC can, in fact, be regarded as old wine in a new bottle, as the idea also drew on earlier attempts in the '90s to measure equity in the finance and delivery of healthcare systems in high-income countries, most of which often subscribed to egalitarian goals. In the lecture, Eddy examined in more detail the extent to which this is true by comparing the original concepts to the latest measures of UHC and why they required adaptation. As well as:

- The notion of payment according to the ability to pay was replaced by the notion of financial protection, and measures of progressivity were turned into measures of impoverishment or catastrophic spending.
- The ethical premise of "equal treatment for equal need, irrespective of ability to pay" evolved into measures trying to get at a depth of coverage that can be adjusted for inequality.
- The (arbitrary) combination of both dimensions into one index of Universal Health Coverage is discussed based on recent data from the WB HEFPI database.

OHE Innovation Prize Award Event

To celebrate 60 years, OHE launched a prize to promote original thinking and solve critical problems in health economics. The inaugural winner, Professor Aidan Hollis, University of Calgary, was announced at a Prize Ceremony last night at the Royal Society of Chemistry on the 24th of January of 2022.

EXTERNAL PRESENTATIONS

No.	Presentation Details
1	Date: 5 th January 2022 Presenter: Chris Sampson Event: HESG winter 2022 Location: Leeds Title: Discussion of 'The impact of Covid-19 lockdowns on the mental health of homeworkers' by Elliott et al. Authors: Chris Sampson
2	Date: 6 th January 2022 Presenter: N/A Event: HESG winter 2022 Location: Leeds Title: Identifying cost-effectiveness thresholds: a review of factors for a new theoretical framework Authors: Chris Sampson, Dimitrios Kourouklis, Mikel Berdud
3	Date: 6 th January 2022 Presenter: Gayathri Kumar Event: HESG Winter 2022 Location: Leeds Title: Discussion: The impact of the 2016 Junior Doctor Contract on the retention of trainee doctors within the English NHS (Mello et al. 2021) Critique of an analysis of impact of new pay structure for junior doctors on staff retention Authors: Gayathri Kumar
4	Date: 6 th January 2022 Presenter: Mireia Jofre-Bonet Event: Health Economists' Study Group meeting winter 2022 Location: Leeds Title: Discussion of "Comparing health service usage of different immigrant groups with native Australians: Evidence from the Household Income and Labour Dynamics Survey" Authors: Brown et al.
5	Date: 19 th January 2022 Presenter: Eleanor Bell Event: Presentation to students and Stepney School Location: Virtual Title: Why a career in health economics? Authors: Eleanor Bell
6	Date: 19 th January 2022 Presenter: Amanda Cole Event: NICE virtual roundtable Location: Virtual Title: Invited expert participant in NICE virtual roundtable event (reviewing their draft "RWE Framework") hosted by NICE and attended by a broad base of experts and stakeholders.
7	Date: 27 th January 2022 Presenter: Mireia Jofre-Bonet Event: Lancaster (UK) Nova (Portugal) joint Seminar Series in Health Economics and Policy Location: Virtual Title: The impact of domestic violence on the health and educational attainment of children Authors: M. Jofre-Bonet, M. Rossello-Roig, V. Serra-Sastre

8	<p>Date: 17th February 2022 Presenter: Adrian Towse Event: Podcast for the Global Health Impact Project Location: Virtual Title: Drugs and Vaccines for Developing Countries The role of differential pricing in increasing access and the evolution of “push” and “pull” incentives to get new drugs and vaccines for global health challenges. Authors: Adrian Towse</p>
9	<p>Date: February 2022 Presenter: Mireia Jofre-Bonet Event: Invited commentary for the Centre of Recerca en Economia de la Salut, Universitat Pompeu Fabra Location: Barcelona, Spain Title: Reflections on the article "Feasibility and attractiveness of indication value-based pricing in key EU countries." Authors: Mireia-Jofre-Bonet</p>
10	<p>Date: 10th March 2022 Presenter: Chris Sampson Event: OHE Webinar Location: Online Title: Do we need animal health economics? An exploration of the ways in which health economists might consider research on animal health. Authors: Chris Sampson, Werner Brouwer, Stefan Lipman, Louise Proud, Hareth Al-Janab</p>
11	<p>Date: 24th March 2022 Presenter: Mikel Berdud Event: Lecture in Health Economics MSc at City University of London Location: London, UK Title: Economics of Pharmaceutical Markets (Part B) R&D process and cost estimation; Market failures and IP protection; Push and Pull incentives (COVID-19 Vaccines, AMR UK pilot, global Health and MVAMC), impact of Orphan Drug EU regulation, Value-based Pricing and incentives for R&D Authors: Mikel Berdud and Dimitrios Kourouklis</p>
12	<p>Date: 8th March 2022 Presenter: Adrian Towse Event: “Looking ahead to the Third Human Genome Editing Summit- Equity & Access”, organised by the UK Royal Society, the UK Academy of Medical Sciences, the US National Academies of Sciences and Medicine and The World Academy of Sciences. Location: Virtual Presentation Title: "What issues should developers and policy makers consider now to promote equitable access to gene editing therapies when they come to market over the next 5 to 10 years?" Authors: Adrian Towse</p>
13	<p>Date: 24th March 2022 Presenter: Dimitrios Kourouklis Event: Lecture in Health Economics MSc at City, University of London Location: Online Presentation title: Economics of Pharmaceutical Markets (Part A) Pharmaceuticals in the context of healthcare, competition models for prescription medicine, R&D, innovation and cost-containment, policy evaluation. Authors: Dimitrios Kourouklis and Mikel Berdud</p>
14	<p>Date: 8th April 2022 Presenter: Dimitrios Kourouklis Event: Department of Statistics and Insurance Seminar Series Location: University of Piraeus Title: Do R&D tax credits impact pharmaceutical innovation? Evidence from a synthetic control approach Authors: Edward Oliver, Dimitrios Kourouklis, Mireia Jofre-Bonet</p>
15	<p>Date: 20th April 2022 Presenter: Nadine Henderson</p>

	<p>Event: EuroQol Early Career Researcher Meeting Location: Noordwijk, The Netherlands Title: Discussant of "COVID-19 Experiences of Pregnant and Postpartum Persons and Their Impact on Health-Related Quality-of-Life". Authors: Sian Besley, Katie Page, Chris Sampson</p>
16	<p>Date: 20th April 2022 Presenter: Nadine Henderson Event: EuroQol Early Career Researchers Meeting Location: Noordwijk, the Netherlands Title: Discussion of Swathi et al. 2022. Another participant discussed the paper "Development of a hearing bolt-on: Qualitative Literature Review." Authors: Nadine Henderson, Chris Sampson, Sian Besley, Katie Page (UTS)</p>
18	<p>Date: 20th April 2022 Presenter: Adrian Towse Event: WVC Virtual Panel: "How can we build a more resilient public health infrastructure for vaccines?" Location: Hybrid – virtual and Washington DC. Title: Four key aspects of a healthy vaccines market Authors: Adrian Towse</p>
19	<p>Date: 6th May 2022 Presenter: Patricia Cubi-Molla Event: EvalAES (SIG on economic evaluation of health and healthcare policies) workshop Location: Barcelona Title: Development of a synthetic index of primary care output in England. Authors: Patricia Cubi-Molla, Margherita Neri, Graham Cookson</p>
20	<p>Date: 15th May 2022 Presenter: Lotte Steuten Event: ISPOR Annual Meeting Location: National Harbor, Maryland (US) Title: Short Course: Early-Stage Health Technology Assessment Authors: Lotte Steuten</p>
21	<p>Date: 15th May 2022 Presenter: Adrian Towse Event: Short Course: Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products. Location: ISPOR 2022, Washington DC. Title: "Theory and Incentives in Risk Sharing" Part of a short course given with Lou Garrison and Josh Carlson of UW. Adrian Towse's section addresses the theory and practice of risk-sharing agreements with case studies. Authors: Adrian Towse</p>
22	<p>Date: 16th May 2022 Presenter: Margherita Neri Event: ISPOR Annual conference 2022 Location: Washington DC Title: Defining and measuring health system pressure: a conceptual framework and application to RSV and C. difficile infections Authors: Neri M, Brassel S, Schirmacher H, Steuten L, Shea K M, Stoychev S, Albuquerque de Almeida F, Charos A, Ben Mehidi I, Schley K</p>
23	<p>Date: 16th May 2022 Presenter: Chris Sampson Event: ISPOR 2022 Location: Washington, D.C. Title: Open Source in Precision Medicine: The Perfect Fit? Authors: Chris Sampson, Susan Snyder, Deborah Marshall, Koen Degeling.</p>
24	<p>Date: 16th May 2022 Presenter: Margherita Neri Event: ISPOR Annual conference 2022</p>

	<p>Location: Washington DC</p> <p>Title: Defining and measuring health system pressure: a conceptual framework and application to RSV and C. difficile infections</p> <p>Authors: Neri M, Brassel S, Schirmacher H, Steuten L, Shea K M, Stoychev S, Albuquerque de Almeida F, Charos A, Ben Mehidi I, Schley K</p>
25	<p>Date: 17th May 2022</p> <p>Presenter: Adrian Towse</p> <p>Event: Issue Panel: Severity Shortfall: Graceful or Awkward? Contextual or Continuous?</p> <p>Location: ISPOR 2022, Washington DC.</p> <p>Title: "Theory and Incentives in Risk Sharing"</p> <p>Authors: Adrian Towse</p>
26	<p>Date: 18th May 2022</p> <p>Presenter: Mireia Jofre-Bonet</p> <p>Event: Masterclass on "The reality and challenges of access to medicines" (Jornada "Realidad y retos en el acceso a medicamentos"), organised by the Association of Catalan Pharmaceutical Industry (Associacio de Farmacia Catalana)</p> <p>Location: Academia de Ciències Mèdiques i de la Salut de Catalunya i de Balears (Barcelona), and online</p> <p>Title: "Strategies for access to medicines: an international perspective" ("Estrategias de acceso en otros países del entorno")</p> <p>Authors: Mireia Jofre-Bonet</p>
27	<p>Date: 18th May 2022</p> <p>Presenter: Adrian Towse</p> <p>Event: Issue Panel: Are Our HTA Methods Fit for Purpose for Gene Therapies?</p> <p>Location: ISPOR 2022, Washington DC.</p> <p>Title: Overview of the challenges associated with the HTA of Gene Therapies and potential solutions – report of OHE's work with European experts</p> <p>Authors: Adrian Towse</p>
28	<p>Date: 8th June 2022</p> <p>Presenter: Adrian Towse</p> <p>Event: Lecture</p> <p>Location: BI Norwegian Business School, Oslo, Norway.</p> <p>Title: New Payment Models. Can we use "conditional", "risk sharing", or "outcome-based" schemes to address uncertainty?</p> <p>Authors: Adrian Towse</p>
29	<p>Date: 14th June 2022</p> <p>Presenter: Margherita Neri</p> <p>Event: Efficiency Research Programme (Round 3) - Health Foundation Advisory Group Meeting</p> <p>Location: Virtual</p> <p>Title: Improving efficiency and labour productivity in primary care: the role of skill mix, technology and patients case-mix</p> <p>Authors: Margherita Neri, Graham Cookson, Patricia Cubi-Molla</p>
30	<p>Date: 20th June 2022</p> <p>Presenter: Dimitrios Kourouklis</p> <p>Event: 21st Annual International Conference on Health Economics, Management & Policy</p> <p>Location: Athens, Greece</p> <p>Title: Do R&D Tax Credits Impact Pharmaceutical Innovation? Evidence from a Synthetic Control Approach</p> <p>Authors: Dimitrios Kourouklis, Edward Oliver, Mireia Jofre-Bonet</p>
31	<p>Date: 22nd June 2022</p> <p>Presenter: Mireia Jofre-Bonet</p> <p>Event: Health Economics Study Group - Summer 2022 Meeting</p> <p>Location: Sheffield</p> <p>Presentation title: Discussion of the paper 'The Impact of Devolution in Greater Manchester on Health, Care, and Wider Determinants of Health: A Whole System Evaluation'.</p> <p>Authors: Philip Britton, Alfariany Fatimah, Alex J Turner, Yiu-Shing Lau, Laura Anselmi, Stephanie Gillibrand, Paul Wilson, and Matt Sutton.</p>

	Research Theme(s) Policy, Organisation and Incentives in Health Systems;
32	Date: 22 nd June 2022 Presenter: Gayathri Kumar Event: HESG Summer 2022 Location: Sheffield Title: "Discussion: What types of economics research do evidence users in health and care need? Recommendations from an NIHR round-table." Authors: Sutton M, Bloor K, Coast J, et al. (working paper)
33	Date: 23 rd June 2022 Presenter: David Mott (Presenting Author) - Jeff Round (Discussant) Event: HESG Location: Sheffield Title: Modelling spillover effects on informal carers: the "carer QALY trap" Authors: David Mott, Hannah Schirrmacher, Hareth Al-Janabi, Andrew Briggs, Sophie Guest, Becky Pennington, Nicolas Scheuer, Koonal Shah, Chris Skedgel
34	Date: 27 th June – 2 nd July 2022 Presenter: Sian Besley Event: ECRD Poster Presentation Location: Virtual Title: Can Changes to Health Technology Assessment Play a Role in Realising the Potential of Gene Therapies? Authors: Sian Besley, Nadine Henderson, Amanda Cole, Adrian Towse, Safiyya Gassman, Lauren Diamond
35	Date: 6 th July 2022 Presenter: Mikel Berdud Event: EUHEA Conference 2022 "Health Economics for sustainable Welfare Systems." Location: Oslo (Norway) Title: The basis for a new theoretical framework to determine cost-effectiveness thresholds for decision making Authors: Chris Sampson, Mikel Berdud, Dimitrios Kourouklis, Chris Skedgel
36	Date: 8 th July 2022 Presenter: Edward Oliver Event: EUHEA Conference 2022 Location: Oslo, Norway Title: The impact of R&D tax credits on pharmaceutical innovation in the UK: a synthetic control approach Authors: E. Oliver, D. Kourouklis, M. Jofre-Bonet
37	Date: 8 th July 2022 Presenter: Margherita Neri Event: EuHEA 2022 Conference Location: Oslo Title: Primary care efficiency and productivity in England: measurement improvements and analysis of determinants Authors: Margherita Neri, Patricia Cubi-Molla, Graham Cookson, Bruce Hollingsworth, Eugenio Zucchelli
38	Date: 11 th July 2022 Presenter: Mireia Jofre-Bonet Event: Panel (Think Tank) on Advanced Therapies in Spain. Panel - Max Brosa, Pharmalex (Spain); Joana Gostkorzewicz Neo, Astrazeneca (Spain); Eva Martin Sanchez Astrazeneca (Spain); Justo Moreno, Astrazeneca (Spain); Jesus Balea (SERGAS); Cristina Ibarrola (Sistema Navarro de Salud); Guillem López-Casasnovas (CRES-UPF); Carlos Mur de Viu (SEDISA), José Luis Poveda (HU La Fe) y José Soto (HC San Carlos y SEDISA). Location: Madrid and zoom Title: Short Overview of New Payment Models for Advanced Therapies in the UK Authors: Mireia-Jofre Bonet
39	Date: 13 th September 2022 Presenter: Sian Besley, Dimitrios Kourouklis

	<p>Event: Partnership for Health System Sustainability and Resilience (PHSSR) Workshop Location: London School of Economics (LSE) Authors: Sian Besley, Dimitrios Kourouklis, Mireia Jofre-Bonet</p>
40	<p>Date: 19th September 2022 Presenter: Mireia Jofre-Bonet Event: VII Expert Programme in Health Policy and Pharmacoeconomics - Healthcare Innovation. Location: Palma, Mallorca, Spain Title: UK Perspective on Advanced Therapies Authors: Miria Jofre-Bonet</p>
41	<p>Date: 22nd September 2022 Presenter: Amanda Cole and Adrian Towse Event: Pfizer [internal] HTA for GTx Masterclass Location: Virtual Title: HTA for GTx Masterclass 1-hour webinar/discussion with Pfizer employees to disseminate and discuss the outputs of our recently completed project on HTA methodology for gene therapies. Presentation by OHE (Amanda Cole), followed by panel discussion and audience questions. Members of the panel: Amanda Cole (OHE), Adrian Towse (OHE), Nate Posner (Director HEOR, Pfizer), Safiyya Gassman (Senior Director Policy & Public Affairs), Ruth Kim (HEOR Rare Disease).</p>
42	<p>Date: 29th September 2022 Presenter: Lotte Steuten Event: AMR Webinar Location: Virtual Title: Can we fix the broken antibiotics market? Authors: Isobel Firth, Nick Crabb, David Glover, Jason Gordon and Lotte Steuten</p>
43	<p>Date: 7th September 2022 Presenter: Lotte Steuten Event: Guest speaker at LS in person Title: Can we make outcomes-based payments a reality in the UK? Authors: Lotte Steuten</p>
44	<p>Date: 10th October 2022 Presenter: Mikel Berdud Event: Lecture to at Master programme for Health Services management and organisation students Location: Public University of Navarre (UPNA) Title: Incentives to tackle AMR Authors: Mikel Berdud</p>
45	<p>Date: 12th Oct 2022 Presenter: Lotte Steuten Event: Pediatric and adult vaccines against COVID-19 - Educational programme Location: Virtual Title: Looking Beyond the Public Health Impact of COVID-19 Topic: Broader value of COVID-19 vaccines Authors: Lotte Steuten</p>
46	<p>Date: 13th October 2022 Presenter: Patricia Cubi-Molla Event: Webinar [block 1: Frontiers in Economic evaluation]. Part of a series of webinars organised by Fundacion Weber and MSD (Spain) Location: Online Presentation title: "Orientar los precios de la innovación a resultados" [Spanish] [Outcome-based payment schemes] Authors: Patricia Cubi-Molla</p>
47	<p>Date: 26th October 2022 Presenter: Eleanor Bell Event: European Digital Medicine Conference 2022 Location: University of Luxembourg Title: Digital Health Landscape: Insights from recent experience in England Authors: Simon Brassel, Priscila Radu, Eleanor Bell, Martina Garau</p>
48	<p>Date: October/November 2022</p>

	<p>Presenter: Amanda Cole Event: UCL Global Business School for Health (GBSH) Executive Education course on Value-Based Healthcare Location: Online education module Title: Amanda delivered two lessons, entitled: (1) Key considerations on the use of data and (2) Paying for value: Aligning payment for medical technologies more closely with patient-level value Authors: Amanda Cole</p>
49	<p>Date: 4th November 2022 Presenter: Chris Sampson Event: SMaRteN Showcase Conference Location: King's College London Title: SMaRteN Resource Use Measurement Tool Authors: Chris Sampson</p>
50	<p>Date: 7th November 2022 Presenter: Eleanor Bell Event: ISPOR Europe Location: Vienna Title: Estimates of the Global COVID-19 Burden and the Value of Broad and Equitable Access to COVID-19 vaccines Authors: Eleanor Bell, Simon Brassel, Edward Oliver, Hannah Schirrmacher, Stuart Carroll, Sofie Arnetorp, Katja Berg, Duncan Darroch-Thompson, Paula Pohja-Hutchinson, Bruce Mungall, Maarten Postma, Lotte Steuten</p>
51	<p>Date: 7th November 2022 Presenter: Chris Sampson Event: ISPOR Europe Location: Vienna, Austria Title: Are Open-source Models Really for Health Technology Assessment and Health Policy? Authors: Chris Sampson, Dalia Dawoud, Koen Degeling, Ramiro Gilardino</p>
52	<p>Date: 7th November 2022 Presenter: Edward Oliver Event: ISPOR Europe 2022 Location: Vienna Title: The Value of Next Generation Sequencing for Lung Cancer in Europe: Findings From a Literature Review Authors: Edward Oliver, Chris Sampson, Priscilla Radu, Lotte Steuten</p>
53	<p>Date: 7th November 2022 Presenter: David Mott Event: ISPOR Europe Location: Vienna, Austria Title: Modelling Spillover Effects on Informal Carers: The 'Carer QALY Trap' Authors: David Mott, Hannah Schirrmacher, Hareth Al-Janabi, Sophie Guest, Becky Pennington, Nicolas Scheuer, Koonal Shah, Chris Skedgel</p>
54	<p>Date: 7th November 2022 Presenter: Lotte Steuten Event: ISPOR EU Location: Vienna Title: REAL-WORLD DATA AT SCALE: HOW MACHINE LEARNING CAN ENABLE LEARNING FROM ALL PATIENTS Topic: This workshop explored the application of machine learning (ML) to efficiently extract information from electronic health records (EHRs) and generate variables for health economic analysis. Authors: Corey Benedum, Maarten IJzerman, Natalia Kunst, Lotte Steuten</p>
55	<p>Date: 7th November 2022 Presenter: Lotte Steuten & Margherita Neri Event: ISPOR EU Location: Virtual/Vienna</p>

	<p>Title: Impact of Modelling the Inclusion of Productivity Losses in Economic Analyses of Vaccines for Clostridioides Difficile Infections and Respiratory Syncytial Virus</p> <p>Topic: To understand the impact of productivity value on the cost-effectiveness of vaccination in the UK, we illustrate the extent to which the incremental costs would change with and without productivity value incorporated.</p> <p>Authors: Lotte Steuten, Fernando Albuquerque de Almeida, Apostolos Charos, Janne Mewes, Nadia Minarovic, Margherita Neri, Kimberly Shea, Sophia Stoychev</p>
56	<p>Date: 8th November 2022</p> <p>Presenter: Lotte Steuten</p> <p>Event: ISPOR EU</p> <p>Location: Vienna</p> <p>Title: Are we turning a blind eye? Challenges in value assessment of gene therapies for inherited retinal disease</p> <p>Topic: Introductory overview of how traditional value assessment is challenged when evaluating gene therapies, using IRD X-linked retinitis pigmentosa as one example, and what solutions may exist based on learnings from various countries and/or other technologies.</p> <p>Authors: Simon Brassel, Caroline Bregman, Avril Daly, Jennifer M Lee, Lotte Steuten</p>
57	<p>Date: 8th November 2022</p> <p>Presenter: Simon Brassel</p> <p>Event: ISPOR Europe 2022</p> <p>Location: Vienna</p> <p>Title: Are We Turning a Blind Eye? Challenges in Value Assessment of Gene Therapies for Inherited Retinal Disease</p> <p>Authors: Simon Brassel, Jake Hitch, Martina Garau</p>
58	<p>Date: 8th November 2022</p> <p>Presenter: Lotte Steuten</p> <p>Event: ISPOR EU</p> <p>Location: Vienna</p> <p>Title: Women in HEOR: achievements, lessons learned and future ambitions</p> <p>Topic: To highlight a 5-year lookback of the Women in HEOR initiative and showcase ways the initiative has brought attention to gender diversity, elevating diversity in the HEOR workforce, and discussion of future directions of the initiative.</p> <p>Authors: Julia F. Slejko, Lotte Steuten, Olivia Wu</p>
59	<p>Date: 8th November 2022.</p> <p>Presenter: Amanda Cole</p> <p>Event: ISPOR Europe 2022</p> <p>Location: Vienna</p> <p>Title: Educational Symposium: Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?</p> <p>Authors: Cole, A., Godfrey, J., Kim, R., Sola-Morales, O. and Towse, A.</p>
60	<p>Date: 8th November 2022</p> <p>Presenter: Sian Besley</p> <p>Event: ISPOR Europe 2022</p> <p>Location: Vienna</p> <p>Title: Healthcare System Sustainability and Resilience: Creating an Index</p> <p>Authors: Sian Besley, Dimitrios Kourouklis, Mireia Jofre-Bonet, Alistair McGuire, George Wharton</p>
61	<p>Date: 8th November 2022</p> <p>Presenter: Adrian Towse</p> <p>Event: ISPOR Europe</p> <p>Location: Vienna</p> <p>Title: How Should the EU Pull Their Weight? Designing and Implementing an Effective Delinked Pull Incentive for Antibiotics in the EU</p> <p>Authors: Adrian Towse</p>
62	<p>Date: 8th November 2022</p> <p>Presenter: Adrian Towse</p> <p>Event: ISPOR Europe</p> <p>Location: Vienna</p>

	Title: Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access? Author Adrian Towse
63	Date: 9 th November 2022 Presenter: Simon Brassel Event: ISPOR Europe 2022 Location: Vienna Title: The international impact of NICE decisions Authors: Simon Brassel, Edward Olliver, Nadine Henderson, Phill O'Neill, Martina Garau
64	Date: 9 th November 2022 Presenter: Mikel Berdud Event: ISPOR Europe Location: Vienna, Austria Title: The Basis for a New Framework to Determine the Cost-Effectiveness Threshold Authors: Chris Sampson, Mikel Berdud, Dimitrios Kourouklis, Chris Skedgel
65	Date: 9 th November 2022 Presenter: Chris Skedgel Event: ISPOR Europe Location: Vienna Title: Should Payers Increase Reimbursement for Treatments for Severe Diseases? Empirical Approaches for Estimating Risk Preferences with Applications to Grace and Insurance Value Authors: Julia Snider, PhD; Jason Shafrin, PhD; Chris Skedgel, PhD
66	Date: 11 th November 2022 Presenter: Amanda Cole Event: Journal of Internal Medicine Think Tank workshop, hosted by the Karolinska Institutet: Are innovative payment models required to give patients access to potential disease-modifying therapies for Alzheimer's disease? Location: Stockholm, Sweden Title: Experience with outcomes-based payment models in chronic progressive disease Topic: Considering what we have learnt from the application of OBP to other chronic disease areas (multiple sclerosis and oncology), and how this could be transferrable to enabling access to disease-modifying Alzheimer's drugs. Author: Amanda Cole
67	Date: 16 th November 2022 Presenter: Margherita Neri Event: Network of Alberta Health Economists (NOAHE) Rounds VI Location: online Presentation title: Realising the broader value of vaccines in health technology assessment (HTA) What was your presentation about? This presentation provided an overview of OHE's work on the 'Broader Value of Vaccines' aiming to improve understanding of the vaccines value paradigm and its recognition in economic evaluations and decision making. Authors: multiple
68	Date: 17 th November 2022 Presenter: Chris Skedgel Event: Centre for Health Economics Location: University of York Title: The Carer QALY Trap in valuing survival gains in patients with informal carers Authors: Chris Skedgel, David Mott, Hannah Schirmacher
69	Date: 17 th November 2022 Presenter: Chris Sampson Event: Lecture for MSc in Translational Health Sciences Location: University of Oxford, Oxford, UK Presentation title: HTA decision making & NICE threshold Authors: Chris Sampson, Lotte Steuten
70	Date: 23 rd November 2022 Presenter: Mireia Jofre-Bonet Event: Partnership for Health Care Systems Sustainability and Resilience Global Summit

	<p>Location: Geneva (and virtual) Title: Assessing and Measuring Sustainability and Resilience of Health Care System Authors: Sian Besley, Dimitrios Kourouklis, Mireia Jofre-Bonet, Alistair McGuire (LSE) and George Wharton (LSE)</p>
71	<p>Date: 29th November 2022 Presenter: Simon Brassel Event: HTAsialink 2022 (Pre-Conference) Location: Pattaya, Thailand (virtual presentation) Title: Value Assessment & Reimbursement of Digital Health Technologies in England Authors: Brassel, S., Radu, P. Bell, E. Garau, M.</p>
72	<p>Date: 30th November 2022 Presenter: Chris Sampson Event: UCL Health Economics Analysis and Research Methods Team (HEART) Christmas event Location: UCL, London, UK Title: Cost-effectiveness thresholds Authors: Chris Sampson</p>
73	<p>Date: 29th November 2022 Presenter: Gayathri Kumar Event: Economics Faculty seminar to undergraduate and postgraduate students Location: Mahatma Gandhi College, Thiruvananthapuram, Kerala, India Presentation title: Value, Affordability and Decision-making: an Introduction to Health Economics Authors: Gayathri Kumar Value, Affordability, and Decision Making;</p>
74	<p>Date: 2-4 December 2022 Presenter: Martina Garau, Gayathri Kumar Event: ESMO Asia Congress 2022 Location: Singapore Presentation title: Oncology combination therapies (CTs) in Asia-Pacific markets: what are the current access challenges?</p>
75	<p>Date: 8th December 2022 Presenter: Amanda Cole Event: ABPI Innovative Payment Models workshop Location: 1 Wimpole Street, Westminster Title: Payment models that could work for patients, industry and the NHS Event convening key stakeholders and representatives from NHSE, DHSC, OLS, academics and Industry to discuss. I will discuss what we have learned about outcome-based payment through our Cancer Research UK work, and lessons learnt that could be applied to ATMPs. Authors: Amanda Cole and Jon Sussex.</p>

ADVISORY ROLES

The number of advisory roles of OHE staff members has continued to grow. It reflects the good standing of OHE members in terms of impacting policy and our recognised contribution to the wider research and policy community. Having an impact and helping steer health policy and decision-making in health economics is an essential OHE charitable object.

OHE STAFF MEMBERSHIP OF ADVISORY PANELS, BOARDS AND COMMITTEES

NICE: Public Health Guidelines Standing Committee – Grace Hampson
NICE: Member of the Expert Advisers Panel for the Centre for Guidelines – Mireia Jofre-Bonet
UKRI/ESRC/MRC – Peer Review College - Mireia Jofre-Bonet
ISPOR: Member of the 'Value of Information' Task Force – Lotte Steuten
NIHR: Steering Committee Member for NIHR/HS&DR Project No. 8/17/1934 – Graham Cookson
NIHR – Member of a Study Steering Committee for the LOGiC – Long term Outcomes for Gender Identity in Children Study – funded by NIHR. Sites: Tavistock and Portman-NHS; UCL; U. Liverpool, U. Cambridge, UCLH - Mireia Jofre-Bonet
NIHR – Member of a Study Steering Committee for ADVANCE - National Addiction Centre Institute of Psychiatry, Psychology and Neuroscience - King's College London- Mireia Jofre-Bonet
NIHR - Member of a Study Steering Committee for the SUpporting Wellbeing Through PEer-Befriending (SUPERB) Trial – City, University of London, and UCLH, Kings College - Mireia Jofre-Bonet
Health Foundation – Member of the Steering Committee for NHS Workforce Retention Project – Graham Cookson
Scientific Experts and Methodologists Group (SEM) Delphi Panel Member of the IMPACT-HTA (WP7) project "Improved methods and actionable tools for enhancing HTA" – Martina Garau
Convener of the Health Economics, Heads of Unit, UK – jointly with Joanne Coast, Mireia Jofre-Bonet
Editorial Board Member, *Applied Health Economics and Health Policy Journal* – Lotte Steuten
PharmacoEconomics: Editorial Board Member – Chris Skedgel
PharmacoEconomics – Open: Editorial Board Member – Chris Sampson
Member ISPOR Finance Committee - Adrian
Chair ISPOR Governance Committee - Adrian
Member ISPOR Health Science Policy Committee - Adrian
Member ISPOR Nominations Committee. - Adrian
Senior Visiting Fellow, Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford – Adrian
Participant in the Efficient and Effective Reduction of Health Inequality Workshop #2, Centre for Health Economics, University of York, which was held via Zoom on Tuesday 10th November 2020 – Mireia member of EuroQol Group Association – David Mott
Co-Chair ISPOR Europe 2021 – Lotte Steuten
Past Chair, ISPOR Special Interest Group on Open Source Models – Chris Sampson
Member of the VIVA panel, for Ph. D. student Angel Fernandez, University of Granada & University of Insubria. Ph.D. advisors: Dolores Jumenez and Silvana Robone.
Director ISPOR Board – Lotte Steuten
Member of a VIVA panel – University of Granada and Sanubria – Patricia Cubi-Molla
Member of PhD VIVA committee for: Eduardo Martínez Gabaldón (University of Murcia, July 2021) - Patricia Cubi-Molla
Steering Group Member of ISPOR Taskforce on Value-Based Healthcare – Lotte
Mireia Jofre-Bonet has been asked to join the Steering Committee of the project 'Antenas de innovación y difusión en Política Sanitaria' (Innovation and Dissemination in Health Policy Radar) led by the Centre de Recerca en Economia de la Salut (CRES) of the Universitat Pompeu Fabra (UPF), sponsored by Astra-Zeneca.
Euroqol Member – Chris Sampson
Amanda is now a member of the ISPOR Health Science Policy Council (Policy Outlook Committee)

VISITING POSITIONS FOR OHE STAFF

Nuffield Department of Population Health, University of Oxford – Senior Visiting Fellow – Adrian Towse
Public University of Navarra – Visiting Researcher – Mikel Berdud
University of Surrey – Visiting Professor – Graham Cookson
Science Policy Research Unit, University of Sussex – Associate Faculty Member – Grace Hampson
City, University of London – Honorary Visiting Professor – Lotte Steuten
City, University of London – Honorary Visiting Professor – Graham Cookson
City, University of London – Professor, Department of Economics – Mireia Jofre-Bonet
City, University of London – Honorary Senior Research Fellow – Patricia Cubí-Mollá
Fred Hutch Cancer Research Center, University of Washington – Affiliate Investigator – Lotte Steuten
University of East Anglia – Honorary Senior Fellow – Chris Skedgel
Centre for Industrial Economics, MINES ParisTech – Research Associate - Dimitrios Kourouklis – renewed 2022-2025
Associate Editor, Frontiers in Health Services (Cost and Resource Allocation) – Chris Sampson
ISPOR - Digital Health Special Interest Group - Simon Brassel

Associated Visiting Researcher, Centre de Recerca en Economia de la Salut (CRES), Universitat Pompeu Fabra, Barcelona, Spain, Mireia-
Review Editor on the Editorial Board of Health Economics of the journal Frontiers in Public Health – Mireia Jofre-Bonet
Senior Associate Researcher, Centre de Recerca en Economia de la Salut (CRES), Universitat Pompeu Fabra, Barcelona, Spain
Renewal of Visiting Professor in Practice at the LSE until 5th September 2025 – Adrian Towse
NHS England Primary Care Transformation Programme: Quantitative Working Group - Graham

EXTERNAL IMPACT

In 2022, OHE's research has continued to have a remarkable impact. Below, we list a sample of those we have an explicit record of:

AMR:

- OHE's research on a new [Transferable Exclusivity Extension](#) for AMR was published by [EFPIA](#)
- OHE contributed to the NICE's AMR pilot by supporting Pfizer (one of the two companies participating in the pilot) in their negotiations with NHS England. On the back of that work, OHE published a blog series on the pilot for a wider audience. OHE also held a webinar with representatives from NICE and NHS England on what the pilot means for the UK and international efforts to combat AMR, which registered over 150 attendees.

Digital Health:

- OHE's real-world evaluation of Sleepio provided the economic evidence underpinning [NICE's first positive decision](#) for a digital therapeutic
- OHE was commissioned by HITAP, the Thai HTA agency, to author a landscape analysis of digital health in the UK, which will be presented at the [European Digital Medicine Conference](#) in October. HITAP's plan is to publish a report drawing from analyses of five countries, to inform the future Digital Health landscape in Thailand. OHE will be co-authors of this report.

Precision oncology:

- OHE's research on precision oncology has been published in [Nature Medicine](#) and [Healthcare](#) and presented at multiple conferences, including [ISPOR](#). Lotte Steuten will present a keynote address at a Precision Oncology Forum in Berlin in December.

In addition, we anticipate having a further impact on a number of key healthcare policy issues in 2023 related to research and consulting work undertaken by OHE in 2022. For example, following work for the Health Foundation on primary care efficiency, OHE has been commissioned by NHSE to develop a new set of primary care productivity indicators which will be used in the new 5-year GP contract.

WEBSITE, INSIGHTS & SOCIAL MEDIA

We have continued to have substantial activity on our website, which has now had a relaunch, and our social media channels are growing. In summary, we have published 40 blogs including work about our research online, as well as new 'insights', and we have achieved the following website stats and social media presence:

- Number of publication downloads (total events): 12,629
- Number of publication downloads (unique events): 11,297
- Number of website visits: 148,863
- Number of website users: 140,619
- LinkedIn Followers: 8032
- Twitter followers: 5577

About us

Founded in 1962 by the Association of the British Pharmaceutical Society, the Office of Health Economics (OHE) is not only the world's oldest health economics research group, but also one of the most prestigious and influential.

OHE provides market-leading insights and in-depth analyses into health economics & health policy. Our pioneering work informs health care and pharmaceutical decision-making across the globe, enabling clients to think differently and to find alternative solutions to the industry's most complex problems.

Our mission is to guide and inform the healthcare industry through today's era of unprecedented change and evolution. We are dedicated to helping policy makers and the pharmaceutical industry make better decisions that ultimately benefit patients, the industry and society as a whole.

OHE. For better healthcare decisions.

Areas of expertise

- Evaluation of health care policy
- The economics of health care systems
- Health technology assessment (HTA) methodology and approaches
- HTA's impact on decision making, health care spending and the delivery of care
- Pricing and reimbursement for biologics and pharmaceuticals, including value-based pricing, risk sharing and biosimilars market competition
- The costs of treating, or failing to treat, specific diseases and conditions
- Drivers of, and incentives for, the uptake of pharmaceuticals and prescription medicines
- Competition and incentives for improving the quality and efficiency of health care
- Incentives, disincentives, regulation and the costs of R&D for pharmaceuticals and innovation in medicine
- Capturing preferences using patient-reported outcomes measures (PROMs) and time trade-off (TTO) methodology
- Roles of the private and charity sectors in health care and research
- Health and health care statistics